

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|---|---|
| <p>(51) International Patent Classification 6 : C07K 7/23, A61K 38/09</p> | <p>A1</p> | <p>(11) International Publication Number: WO 98/55505 (43) International Publication Date: 10 December 1998 (10.12.98)</p> |
| <p>(21) International Application Number: PCT/EP98/02802 (22) International Filing Date: 6 May 1998 (06.05.98) (30) Priority Data: 97401212.2 2 June 1997 (02.06.97) BP (34) Countries for which the regional or international application was filed: FR et al. (71) Applicant (for all designated States except US): LABO- RATOIRE THERAMEX [MC/MC]; 6, avenue Prince Héréditaire Albert, MC-98000 Monaco (MC). (72) Inventors; and (75) Inventors/Applicants (for US only): DELANSORNE, Rémi [FR/FR]; 7 ter, avenue Edith Cavell, F-06000 Nice (FR). PARIS, Jacques [FR/FR]; 31, avenue Cap de Croix, F-06100 Nice (FR). (74) Agents: NEVANT, Marc et al.; Cabinet Beau de Loménie, 158, rue de l'Université, F-75340 Paris Cedex 07 (FR).</p> | <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. With amended claims.</p> | |
| <p>(54) Title: LH-RH PEPTIDE ANALOGUES, THEIR USES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM (57) Abstract The invention relates to LH-RH peptide analogues with excellent affinity for LH-RH receptors, of formula (I): A1-A2-A3-A4-A5-A6-HAA-A7-Pro-Z in which Z, A1 to A7 are specified in the description and HAA is a non-aromatic hydrophobic amino acid having from 7 to 20 carbon atoms. The invention also relates to the uses of said peptide analogues and to the pharmaceutical compositions containing them.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

LH-RH peptide analogues, their uses and pharmaceutical compositions containing them

This invention relates to LH-RH peptide analogues, to their use and to pharmaceutical compositions in which they are present.

LH-RH, or luteinizing hormone-releasing hormone, is a neurohumoral hormone produced in the hypothalamus which stimulates the secretion of the gonadotrophins, LH (luteinizing hormone) and FSH (follicle-stimulating hormone), which in turn regulate the endocrine and exocrine functions of the ovary in the female, and of the testis in the male. It has the following structural formula :

1 2 3 4 5 6 7 8 9 10

pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂

Historically (Karten and Rivier, Endocr. Rev., 1986, 7(1), 44-66), synthetic improvement of LH-RH activity has been achieved first, by replacement of the C-terminal glycineamide by an ethylamide directly bound to Pro⁹, and then, by introduction of D-Ala in position 6. Both independent breakthroughs yielded analogs each about 5 times more active than LH-RH. All therapeutically useful agonists result from further major improvement in position 6 with the introduction of hydrophobic aliphatic or aromatic D-amino acids instead of D-Ala, with or without the combined Pro⁹-N-ethylamide modification. On this C-terminal end, only slight improvements have been obtained with fluorinated amides or with azaglycinamide. Replacement of Trp in position 3 by INal has been reported (Karten and Rivier, 1986, cf above) to give an agonist twice as potent as LH-RH, without further synthetic or therapeutic developments.

The only other individual amino acid modification noticed to increase the biological activity of some agonists was found in position 7. Thus, N-methylation of Leu⁷ in LH-RH itself did not increase its potency, but enhanced the activity of some already potent synthetic agonists with certain D-amino acids in position 6 such as D-Trp (Karten and Rivier, 1986, cf above) ; furthermore, charged and bulkier L-amino acids than leucine (Ser(OBu^t), Asp(O-Bu^t), Glu(O-Bu^t), BocLys) somewhat improved the activity of [des-Gly¹⁰; Pro⁹-N-ethylamide]-LH-RH but reduced the potency of 6-modified agonists (Karten and Rivier, 1986, cf above).

As far as antagonists are concerned, numerous modifications in all positions but Pro⁹, and a wide variety of combinations among them, have been tried with unequal success to achieve inhibition of endogenous LH-RH activity (Dutta, Drugs of the Future,

1988, 13(8), 761-787 ; Karten and Rivier, Endoc. Rev., 1986, 7(1), 44-66). For example, antide, a standard potent LH-RH antagonist, results from amino acid changes in positions 1, 2, 3, 5, 6, 8 and 10. N-methylation of Leu⁷ brought about a decrease in potency, and the only changes in this position reported to increase it (2-fold maximum) were the replacement of Leu⁷ by Trp⁷ or Phe⁷.

It has now been found that the replacement of Leu⁷ by highly hydrophobic amino acids, increases the activity of LH-RH itself or of known highly active analogues (agonists or antagonists) of LH-RH.

Especially, it has been found that the replacement of Leu⁷ by adamantylalanine (Ada) or neopentylglycine (Npg) increases the activity of LH-RH itself and makes it possible to obtain analogs with a high affinity for the LH-RH receptors. More specifically, the [Npg⁷]-LH-RH analogues of this invention are potent LH-RH agonists / antagonists *in vivo*.

Thus, according to one aspect of the present invention, LH-RH peptide analogues with high affinity for the LH-RH receptors are provided, in which a non-aromatic hydrophobic amino acid having from 7 to 20 carbon atoms, such as for example Ada⁷ or, preferably, Npg⁷ is substituted for Leu⁷. Preferably these peptide analogues are of the formula (SEQ ID N° : 1):



in which:

- A1 is pGlu ; D-pGlu ; Sar ; AcSar ; Pro or a derivative thereof such as AcPro, ForPro, OH-Pro, Ac-OH-Pro, dehydro-Pro or Ac-dehydro-Pro ; Ser ; D-Ser ; Ac-D-Ser ; Thr ; D-Thr ; Ac-D-Thr ; or an aromatic D-amino acid which may be acylated, such as D-Phe, D-HPhe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-Bal, D-Pal, D-4Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;
- A2 is a direct bond ; His ; or an aromatic D-amino acid such as D-Phe, D-HPhe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-Bal, D-Pal, D-4Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;

3

- A3 is an aromatic L- or D-amino acid such as Phe, HPhe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal, 4Pal or Qal, where Phe and Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;

- A4 is Ala, Ser, D-Ser, MeSer, Ser(OBu^t), Ser(OBzl) or Thr;

5 - A5 is an aromatic L-amino acid such as Phe, HPhe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal, 4Pal or Qal, where Phe and Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups ; or a basic L- or D-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HClit, APhe or ACha, where Arg and HArg may be N-substituted by a (C₁-C₆)alkyl or a (C₃-C₆)cycloalkyl
10 group on one or both nitrogen atoms, and where Orn, Lys, HLys, APhe and ACha may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a nicotinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-azaglycyl, furyl, glycyl-furyl, furyl-azaglycyl, pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group;

15 - A6 is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu^t) ; D-Asp(OBu^t) ; D-Glu(OBu^t) ; D-Thr(OBu^t) ; D-Cys(OBu^t) ; D-Ser(OR₁) where R₁ is a sugar moiety ; an aza-amino acid such as azaGly or azaAla ; D-His which may be substituted on the imidazole ring by a (C₁-C₆)alkyl or by a (C₂-C₇)acyl group ; an aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl
20 side chain such as D-Ala, D-Abu, D-Aib, D-3Aib, D-Val, D-Nva, D-Leu, D-Ile, D-Tle, D-Nle, D-Hol, D-Npg, D-CPa, D-Cpa, D-Cba or D-Cha ; an aromatic D-amino acid such as D-Phe, D-HPhe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-anthryl-Ala, D-phenanthryl-Ala, D-benzhydryl-Ala, D-fluorenyl-Ala, D-Bal, D-Pal, D-4Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-
25 C₄)alkoxy, nitro or trifluoromethyl groups ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic L- or D-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HClit, APhe or ACha, where Arg and HArg may be N-substituted by a (C₁-C₆)alkyl or a (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where Orn, Lys, HLys, APhe and ACha may be N-substituted by one or two
30 (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a nicotinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-azaglycyl, furyl, glycyl-furyl, furyl-azaglycyl,

pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group;

- HAA is a non-aromatic hydrophobic amino acid of from 7 to 20 carbon atoms;


- A7 is a basic L- or D-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HCit, APhe or ACha, where Arg or HArg may be N-substituted by a (C₁-C₆)alkyl or a (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where Orn, Lys, HLys, APhe or ACha may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a nicotinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-azaglycyl, furyl, glycyl-furyl, furyl-azaglycyl, pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group;

- Z is GlyNH₂; D-AlaNH₂; azaGlyNH₂; or a group -NHR₂ where R₂ is a (C₁-C₄)alkyl which may be substituted by an hydroxy or one or several fluorine atoms, a (C₃-C₆)cycloalkyl, or a heterocyclic radical selected from morpholinyl, pyrrolidinyl and piperidyl;

- as well as their pharmaceutically acceptable salts.

In these peptide analogues, HAA is preferably Ada or Npg which may be N-alpha-substituted by a (C₁-C₄)alkyl group optionally substituted by one or several fluorine atoms, Npg being especially preferred.

- A preferred group of peptide analogues (I) comprises the peptides of the formula (SEQ ID N° : 6) :



in which :

- A1 is pGlu; D-pGlu; Sar; AcSar; Pro or a derivative thereof such as AcPro, ForPro, OH-Pro, Ac-OH-Pro, dehydro-Pro or Ac-dehydro-Pro; Ser; D-Ser; Ac-D-Ser; Thr; D-Thr; Ac-D-Thr; or an aromatic D-amino acid which may be acylated, such as D-Phe, D-Tyr, D-Trp, D-Nal, D-INal, D-diphenyl-Ala, D-Bal, D-Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;
- A2 is a direct bond; His; or an aromatic D-amino acid such as D-Phe, D-Tyr, D-Trp, D-Nal, D-INal, D-diphenyl-Ala, D-Bal, D-Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;

5

- A3 is an aromatic L- or D-amino acid such as Phe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal or Qal, where Phe and Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;

- A4 is Ala, Ser, D-Ser, MeSer, Ser(OBu^t), Ser(OBzl) or Thr;

5 - A5 is an aromatic L-amino acid such as Phe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal or Qal, where Phe and Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups ; or a basic L- or D-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HClit, APhe or ACha, where Arg and HArg may be N-substituted by a (C₁-C₆)alkyl or a (C₃-C₆)cycloalkyl group on one or both
10 nitrogen atoms, and where Orn, Lys, HLys, APhe and ACha may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a nicotinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-azaglycyl, furyl, glycyl-furyl, furyl-azaglycyl, pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group;

15 - A6 is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu^t) ; D-Asp(OBu^t) ; D-Glu(OBu^t) ; D-Thr(OBu^t) ; D-Cys(OBu^t) ; D-Ser(OR₁) where R₁ is a sugar moiety ; an aza-amino acid such as azaGly or azaAla ; D-His which may be substituted on the imidazole ring by a (C₁-C₆)alkyl or by a (C₂-C₇)acyl group ; an aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl
20 side chain such as D-Ala, D-Abu, D-Aib, D-3Aib, D-Val, D-Nva, D-Leu, D-Ile, D-Tle, D-Nle, D-Hol, D-Npg, D-CPa, D-Cpa, D-Cba or D-Cha ; an aromatic D-amino acid such as D-Phe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-anthryl-Ala, D-phenanthryl-Ala, D-benzhydryl-Ala, D-fluorenyl-Ala, D-Bal, D-Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic L- or D-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HClit, APhe or ACha, where Arg and HArg may be N-substituted by a (C₁-C₆)alkyl or a (C₃-C₆)cycloalkyl group on one or both nitrogen
25 atoms, and where Orn, Lys, HLys, APhe and ACha may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a nicotinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-azaglycyl, furyl, glycyl-furyl, furyl-azaglycyl,
30

pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group;

- Npg may be N-alpha-substituted by a (C₁-C₄)alkyl group which may be substituted by one or several fluorine atoms;

5 - A7 is a basic L- or D-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, H₂Cit, APhe or ACha, where Arg or HArg may be N-substituted by a (C₁-C₆)alkyl or a (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where Orn, Lys, HLys, APhe or ACha may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a nicotinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-
10 azaglycyl, furyl, glycyl-furyl, furyl-azaglycyl, pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group;

 - Z is GlyNH₂ ; D-AlaNH₂ ; azaGlyNH₂ ; or a group -NHR₂ where R₂ is a (C₁-C₄)alkyl which may be substituted by an hydroxy or one or several fluorine atoms, a (C₃-C₆)cycloalkyl, or a heterocyclic radical selected from morpholinyl, pyrrolidinyl and
15 piperidyl;

as well as their pharmaceutically acceptable salts.

In the present description the term "(C₁-C₄)alkyl" denotes methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl and t-butyl groups.

The term "(C₁-C₆)alkyl" denotes methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, s-pentyl, t-pentyl and hexyl groups.
20

The term "(C₁-C₈)alkyl" denotes methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, s-pentyl, t-pentyl, hexyl, heptyl and octyl groups ;

The term "(C₁-C₄)alkoxy" denotes a group -OR where R is a (C₁-C₄)alkyl.

25 The term "(C₂-C₇)acyl" denotes a group -COR where R is a (C₁-C₆)alkyl.

The term "(C₃-C₆)cycloalkyl" denotes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups.

The term "sugar moiety" denotes D- or L-pentoses or hexoses and their amino-derivatives.

30 The term "LH-RH analogues" denotes peptides in which at least one amino acid has been modified in the sequence of LH-RH.


The term "non-aromatic hydrophobic amino acid" denotes a linear, branched or cyclic amino acid with a side chain of from 5 to 18, more preferably 5 to 11 carbon atoms (beginning at the β -carbon included) ; the hydrophobic nature of a suitable amino-acid can be defined by a positive difference of at least 0.5 when compared with leucine, in either log P (P : partition coefficient in the n-octanol/water system) or the Hansch hydrophobicity constant π .

In the present description and in the claims, the following abbreviations are used :

| | |
|--|---|
| Abu : 2-aminobutyric acid | Ac : acetyl |
| ACha : aminocyclohexylalanine | Aib : 2-aminoisobutyric acid |
| 3Aib : 3-aminoisobutyric acid | Ala : alanine |
| AlaNH ₂ : alaninamide | APhe : p-aminophenylalanine |
| Arg : arginine | Asp : aspartic acid |
| azaAla : aza-alanine | azaGly : aza-glycine |
| azaGlyNH ₂ : azaglycinamide | Bal : benzothienylalanine |
| Boc : <i>tert</i> -butoxycarbonyl | Cba : cyclobutylalanine |
| Cha : cyclohexylalanine | Cit : citrulline |
| CPa : cyclopropylalanine | Cpa : cyclopentylalanine |
| Fmoc : fluorenylmethoxycarbonyl | For : formyl |
| Glu : glutamic acid | Gly : glycine |
| GlyNH ₂ : glycineamide | HArg : homoarginine |
| HCit : homocitrulline | His : histidine |
| HLys : homolysine | Hol : homoleucine |
| Ile : isoleucine | IprLys : N ^ε -isopropyllysine |
| Leu : leucine | Lys : lysine |
| MeSer : N-methylserine | Met : methionine |
| Nal : 3-(2-naphtyl)alanine | 1Nal : 3-(1-naphtyl)alanine |
| NEt : N-ethylamide | NicLys : N ^ε -nicotinoyllysine |
| Nle : norleucine | Npg : neopentylglycine |
| Nva : norvaline | OBu ^t : <i>tert</i> -butoxy |
| OBzl : benzyl ester | Orn : ornithine |
| Pal : 3-(3-pyridyl)alanine | pClPhe : 3-(4-chlorophenyl)alanine |

| | |
|-----------------------------------|------------------------------------|
| Pen : penicillamine | pGlu : pyroglutamic acid |
| Phe : phenylalanine | Pro : proline |
| Qal : 3-(3-quinolyl)alanine | Sar : sarcosine |
| Ser : serine | (S-Me)Pen : S-methyl-penicillamine |
| (S-Et)Pen : S-ethyl-penicillamine | Thr : threonine |
| Tle : tert-leucine | Trp : tryptophan |
| Tyr : tyrosine | Val : valine |
| Ada : adamantylalanine | HPhe : homophenylalanine |
| MeNpg : N-methylnopentylglycine | 4Pal : 3-(4-pyridyl)alanine |

A preferred group of peptide analogues according to the invention, having LH-RH agonist activity, comprises the peptides of the formula (SEQ ID N° : 2):



5 in which:

- A1 is pGlu, Sar or AcSar;
- A2 is His;
- A3 is an aromatic L-amino acid such as Phe, HPhe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal, 4Pal or Qal, where Phe and Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;
- A4 is Ala, Ser, D-Ser, MeSer, Ser(OBu^t), Ser(OBzl) or Thr;
- A5 is an aromatic L-amino acid such as Phe, HPhe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal, 4Pal or Qal, where Phe and Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;
- A6 is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu^t) ; D-Asp(OBu^t) ; D-Glu(OBu^t) ; D-Thr(OBu^t) ; D-Cys(OBu^t) ; D-Ser(OR₁) where R₁ is a sugar moiety ; an aza-amino acid such as azaGly or azaAla ; D-His which may be substituted on the imidazole ring by a (C₁-C₆)alkyl or by a (C₂-C₇)acyl group ; an aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl side chain such as D-Ala, D-Abu, D-Aib, D-3Aib, D-Val, D-Nva, D-Leu, D-Ile, D-Tle, D-Nle, D-Hol, D-Npg, D-CPa, D-Cpa, D-Cba or D-Cha ; an aromatic D-amino acid such as D-Phe, D-HPhe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-anthryl-Ala, D-phenanthryl-Ala, D-benzhydryl-Ala, D-fluorenyl-Ala, D-Bal, D-Pal, D-4Pal or D-Qal,

where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic D-amino acid such as D-Arg, D-HArg, D-Orn, D-Lys, D-HLys, D-Cit, D-HCit, D-APhe or D-ACha, where D-Arg and D-HArg may be N-substituted by a (C₁-C₆)alkyl or a (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where D-Orn, D-Lys, D-HLys, D-APhe and D-ACha may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a Fmoc or Boc group;

- HAA is as defined for (I);

10 - A7 is a basic L-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HCit, APhe or ACha;

- Z is GlyNH₂ ; azaGlyNH₂ ; or a group -NHR₂ where R₂ is a (C₁-C₄)alkyl which may be substituted by an hydroxy or one or several fluorine atoms, a (C₃-C₆)cycloalkyl or a heterocyclic radical selected from morpholinyl, pyrrolidinyl and piperidyl;

15 as well as their pharmaceutically acceptable salts.

In these peptide analogues, HAA is preferably Ada or Npg which may be N-alpha-substituted by a (C₁-C₄)alkyl group optionally substituted by one or several fluorine atoms, Npg being especially preferred.

A preferred group of peptide analogues (IIa) comprises the peptides of the formula
20 (SEQ ID N° : 7) :



in which :

A1 is pGlu, Sar or AcSar;

- A2 is His;

25 - A3 is an aromatic L-amino acid such as Phe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal or Qal, where Phe and Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;

- A4 is Ala, Ser, D-Ser, MeSer, Ser(OBu^t), Ser(OBzl) or Thr;

30 - A5 is an aromatic L-amino acid such as Phe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal or Qal, where Phe and Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;


- A6 is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu^t) ; D-Asp(OBu^t) ; D-Glu(OBu^t) ; D-Thr(OBu^t) ; D-Cys(OBu^t) ; D-Ser(OR₁) where R₁ is a sugar moiety ; an aza-amino acid such as azaGly or azaAla ; D-His which may be substituted on the imidazole ring by a (C₁-C₆)alkyl or by a (C₂-C₇)acyl group ; an aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl side chain such as D-Ala, D-Abu, D-Aib, D-3Aib, D-Val, D-Nva, D-Leu, D-Ile, D-Tle, D-Nle, D-Hol, D-Npg, D-CPa, D-Cpa, D-Cba or D-Cha ; an aromatic D-amino acid such as D-Phe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-anthryl-Ala, D-phenanthryl-Ala, D-benzhydryl-Ala, D-fluorenyl-Ala, D-Bal, D-Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic D-amino acid such as D-Arg, D-HArg, D-Orn, D-Lys, D-HLys, D-Cit, D-HCit, D-APhe or D-ACha, where D-Arg and D-HArg may be N-substituted by a (C₁-C₆)alkyl or a (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where D-Orn, D-Lys, D-HLys, D-APhe and D-ACha may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a Fmoc or Boc group;

- Npg may be N-alpha-substituted by a (C₁-C₄)alkyl group which may be substituted by one or several fluorine atoms;

- A7 is a basic L-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HCit, APhe or ACha;

- Z is GlyNH₂ ; azaGlyNH₂ ; or a group -NHR₂ where R₂ is a (C₁-C₄)alkyl which may be substituted by an hydroxy or one or several fluorine atoms, a (C₃-C₆)cycloalkyl or a heterocyclic radical selected from morpholinyl, pyrrolidinyl and piperidyl; as well as their pharmaceutically acceptable salts.

Another preferred group of peptide analogues according to the invention, having LH-RH antagonistic activity, comprises the peptides of the formula (SEQ ID N° : 3):



in which:

- A1 is pGlu ; D-pGlu ; Sar ; AcSar ; Pro or a derivative thereof such as AcPro, ForPro, OH-Pro, Ac-OH-Pro, dehydro-Pro or Ac-dehydro-Pro ; Ser ; D-Ser ; Ac-D-Ser ; Thr ; D-Thr ; Ac-D-Thr ; or an aromatic D-amino acid which may be acylated such as

D-Phe, D-HPhe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-Bal, D-Pal, D-4Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;

5 - A2 is a direct bond or an aromatic D-amino acid such as D-Phe, D-HPhe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-Bal, D-Pal, D-4Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;

10 - A3 is an aromatic L- or D-amino acid such as Phe, HPhe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal, 4Pal or Qal, where Phe and Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;

- A4 is Ala, Ser, D-Ser, MeSer, Ser(OBu^t), Ser(OBzl) or Thr;

15 - A5 is an aromatic L-amino acid such as Phe, HPhe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal, 4Pal or Qal, where Phe and Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups ; or a basic L- or D-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HCit, APhe or ACha, where Arg and HArg may be N-substituted by a (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where Orn, Lys, HLys, APhe and ACha may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a nicotinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-azaglycyl, furyl, glycyl-
20 furyl, furyl-azaglycyl, pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group;

25 - A6 is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu^t) ; D-Asp(OBu^t) ; D-Glu(O-Bu^t) ; D-Thr(O-Bu^t) ; D-Cys(O-Bu^t) ; D-Ser(O-R₁) where R₁ is a sugar moiety ; an aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl side chain such as D-Ala, D-Abu, D-Aib, D-3Aib, D-Val, D-Nva, D-Leu, D-Ile, D-Tle, D-Nle, D-Hol, D-Npg, D-CPa, D-Cpa, D-Cba or D-Cha ; an aromatic D-amino acid such as D-Phe, D-HPhe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-anthryl-Ala, D-phenanthryl-Ala, D-benzhydryl-Ala, D-fluorenyl-Ala, D-Bal, D-Pal, D-4Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or
30 more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic L- or D-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HCit, APhe or ACha, where

Arg and HArg may be N-substituted by a (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where Orn, Lys, HLys, APhe and ACha may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a nicotinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-azaglycyl, furyl, glycyl-furyl, furyl-azaglycyl, pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group;

- HAA is as defined for (I);

- A7 is a basic L- or D-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HCit, APhe or ACha, where Arg and HArg may be N-substituted by a (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where Orn, Lys, HLys, APhe and ACha may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a nicotinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-azaglycyl, furyl, glycyl-furyl, furyl-azaglycyl, pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group;

- Z is GlyNH₂ or D-AlaNH₂;

as well as their pharmaceutically acceptable salts.

In these peptide analogues, HAA is preferably Ada or Npg which may be N-alpha-substituted by a (C₁-C₄)alkyl group optionally substituted by one or several fluorine atoms, Npg being especially preferred.

A preferred group of peptide analogues (IIb) comprises the peptides of the formula (SEQ ID N° : 8) :



in which :

- A1 is pGlu ; D-pGlu ; Sar ; AcSar ; Pro or a derivative thereof such as AcPro, ForPro, OH-Pro, Ac-OH-Pro, dehydro-Pro or Ac-dehydro-Pro ; Ser ; D-Ser ; Ac-D-Ser ; Thr ; D-Thr ; Ac-D-Thr ; or an aromatic D-amino acid which may be acylated such as D-Phe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-Bal, D-Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;

- A2 is a direct bond or an aromatic D-amino acid such as D-Phe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-Bal, D-Pal or D-Qal, where D-Phe and D-Trp may

be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;

- A3 is an aromatic L- or D-amino acid such as Phe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal or Qal, where Phe and Trp may be substituted by one or more halogens,
5 (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;

- A4 is Ala, Ser, D-Ser, MeSer, Ser(OBu^t), Ser(OBzl) or Thr;

- A5 is an aromatic L-amino acid such as Phe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal or Qal, where Phe and Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups ; or a basic L- or D-amino acid
10 such as Arg, HArg, Orn, Lys, HLys, Cit, HCit, APhe or ACha, where Arg and HArg may be N-substituted by a (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where Orn, Lys, HLys, APhe and ACha may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a nicotinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-azaglycyl, furyl, glycyl-furyl, furyl-
15 azaglycyl, pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group;

- A6 is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu^t) ; D-Asp(OBu^t) ; D-Glu(O-Bu^t) ; D-Thr(O-Bu^t) ; D-Cys(O-Bu^t) ; D-Ser(O-R₁) where R₁ is a sugar moiety ; an aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl side chain such as D-Ala, D-Abu, D-Aib, D-3Aib, D-Val, D-Nva, D-Leu, D-Ile, D-Tle, D-Nle, D-Hol, D-Npg, D-CPa, D-Cpa, D-Cba or D-Cha ; an aromatic D-amino acid such as D-Phe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-anthryl-Ala, D-phenanthryl-Ala, D-benzhydryl-Ala, D-fluorenyl-Ala, D-Bal, D-Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more
25 halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic L- or D-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HCit, APhe or ACha, where Arg and HArg may be N-substituted by a (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where Orn, Lys, HLys, APhe and ACha may be N-
30 substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a nicotinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-azaglycyl, furyl, glycyl-

furyl, furyl-azaglycyl, pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group;

- Npg may be N-alpha-substituted by a (C₁-C₄)alkyl group which may be substituted by one or several fluorine atoms;

- 5 - A7 is a basic L- or D-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HCit, APhe or ACha, where Arg and HArg may be N-substituted by a (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where Orn, Lys, HLys, APhe and ACha may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a nicotinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-azaglycyl, furyl, glycyl-furyl, furyl-azaglycyl, pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 10 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group;

- Z is GlyNH₂ or D-AlaNH₂;

as well as their pharmaceutically acceptable salts.

Among the peptide analogues of formula (IIa), those of the formula (SEQ ID N° :

15 4):



in which :

- A3 and HAA are as defined for (IIa) ;


- A6 is Gly ; an aliphatic D-amino acid with a (C₁-C₈)alkyl side chain ; or an
20 aromatic D-amino acid ;

- Z is GlyNH₂ or a group -NHC₂H₅ ;

and their pharmaceutically acceptable salts,
are especially preferred.

- Among the peptide analogues of formula (IIIa), those where A3 is Trp are
25 preferred ; among the latter, those where HAA is Npg which may be N-alpha-methylated, are especially preferred.

Among the peptides of formula (IIb), those of the formula (SEQ ID N° : 5):



in which :

- 30 - A5 and A7 are as defined above for (IIb) ;

- A6 is Gly or a basic L- or D-amino acid ;

- HAA is as defined for (IIb);

and their pharmaceutically acceptable salts,
are especially preferred.

Among the peptide analogues of formula (IIIb), those where HAA is Npg which may be N-alpha-methylated, are preferred.

5 Examples of the salts with pharmaceutically acceptable acids are those with mineral acids, such as for example the hydrochloride, hydrobromide, sulfate, phosphate, borate, hydrogensulfate, dihydrogenphosphate or nitrate, and those with organic acids, such as for example the acetate, oxalate, tartrate, succinate, maleate, fumarate, gluconate, citrate, pamoate, malate, ascorbate, benzoate, p-toluenesulfonate or
10 naphthalenesulfonate.

Examples of the salts with pharmaceutically acceptable bases are those with alkali or alkaline earth metals such as sodium, potassium, calcium or magnesium, and those with organic bases such as amines, trometamol, N-methylglutamine, and the like.

The peptides according to the present invention can be prepared by the well-
15 known techniques of peptide chemistry such as for example peptide synthesis in solution or solid phase peptide synthesis. In general, these techniques involve the stepwise addition of one or more amino acids -which may be suitably protected- to a forming peptide chain.

Preferably, the peptides according to the invention are synthesized using stepwise
20 solid phase synthesis (1,2) with N- α -Fmoc protection. For example, the peptides are assembled on a 4-methylbenzylhydramine resin (Peninsula Laboratories, UK) or on an aminomethyl resin (Peninsula Laboratories, UK). The C-terminal proline is introduced as 4-(Boc-Prolyloxymethyl)phenyl acetic acid. Subsequent removal of the Boc protecting group is achieved with trifluoroacetic acid followed by dichloromethane and
25 dimethylformamide (DMF) washing as well as diisopropylethylamine neutralization. It is also possible to use a "Rink" resin (4-(2',4'-dimethoxyphenyl)-Fmoc-aminomethylphenoxy resin) using Fmoc strategy of synthesis (2).

The synthesis comprises assembling, cleavage and purification steps, as described below :

30

I. Assembling

For all the peptides the following deprotection/coupling procedure is used :

- 1 - DMF washing (3 times - 1 min.)
- 2 - Piperidine 25 % in DMF (1 min.)
- 3 - Piperidine 25 % in DMF (twice - 15 min.)
- 4 - DMF washing (7 times - 1 min.)

5 For each step 15 ml of solvent per gram of peptide resin are used.

Coupling of all amino acid (three fold excess) is performed in DMF in the presence of BOP, Hobt and DIEA (3). Each coupling step is controlled for completion by the ninhydrine test (4) and double coupling is performed if necessary. If, after the second coupling the test still remains positive, the resin is acetylated (acetic acid anhydride, 10 fold excess and DIEA).

Generally, a trifluoroacetic acid (TFA) treatment is performed prior to the deprotection/cleavage step.

II. Cleavage

The peptides are cleaved from the resin and fully deprotected by a treatment with either liquid hydrogen fluoride (HF) or TFA. 10 ml of HF or TFA per gram of peptide resin are used classically at 0° C for 45 min. or 2.5 hours, respectively, in the presence of p-cresol and ethanedithiol (for tryptophan-containing peptides) as scavengers.

After evaporation of the HF, the crude reaction mixture is washed with diethyl ether, dissolved in TFA, precipitated with diethyl ether and dried under reduced pressure.

If need be, prior to HF deprotection the peptide is cleaved from the resin and subsequently amidated by a treatment with ethylamine (5 ml ethylamine per gram of peptide resin, - 78°C, 20 hours).

When a benzyl group is present in the final product, TFA is used (10 ml per gram of peptide resin, 0° C, 2,5 hours) for the final cleavage/deprotection.

The composition of the TFA cleavage mixture in v % is the following :

| | |
|---------------|----------|
| TFA | : 83.3 % |
| Ethanedithiol | : 2.1 % |
| Thioanisol | : 4.2 % |
| Water | : 4.2 % |
| Phenol | : 6.2 % |

17

After filtration of the resin, the peptide is precipitated from the reaction mixture by addition of a large amount of diethylether. After several washings with diethylether the crude peptide is dried under reduced pressure.

III. Purification

5 All the peptides are purified by reverse phase liquid chromatography.

The general procedure of purification is identical for each peptide ; however the gradient of organic solvent is adjusted depending on the initial retention time of the peptide.

General conditions of purification :

| | | |
|----|---------------------|--|
| 10 | Equipment | : KRONWALD SPERATIONSTECHNIK, Medium Pressure liquid chromatography system (Germany) equipped with Glass column. |
| | Stationnary phase | : silica Bondapack C18 (Waters) 15-25 μ m, 100 A |
| | Size of column | : 40 x 340 mm |
| 15 | Elution conditions: | Mobile phase: Eluant A : 0.1 % TFA in water Eluant B : CH ₃ CN/A 60/40 (volume) |
| | Temperature | : Room |
| | Flow rate | : 40 ml |
| | Detection | : UV 210 nm |
| 20 | Fractionning | : 5 ml per fraction |

All fractions containing the target compound are individually analyzed by analytical HPLC. The fractions with a purity higher than 95 % are pooled and freeze-dried. In case the requested purity is not reached after the first purification step, a second purification step and, if need be, a third purification step are performed. The conditions
25 of purification for the second and third steps are similar as those described above except that the slope of the gradient is modified in order to increase the resolution.

After lyophilisation, all purified peptides are present as their trifluoroacetate salt. The final powder corresponding to each peptide is controlled by analytical HPLC. The structure of each compound is also assessed by mass spectral analysis and the net
30 peptide content is determinated by UV absorption.

The peptides according to the present invention have a potent affinity for the LH-RH receptors.

This affinity has been determined according to the following method :

Pituitaries from female Sprague Dawley rats were removed and homogenized with a Potter homogenizer in a 25 mM HEPES buffer (pH 7.4) containing 0.32 M sucrose, 100 µg/l PMSF (phenylmethylsulfonylfluoride), 5.6 U/l aprotinin and 10 000 U/l bacitracin. The homogenates were centrifuged at 700 g for 10 minutes and the supernatants were further centrifuged at 12,500 g for 30 minutes. The pellets were homogenized and centrifuged as described above, but in the same buffer without sucrose.

All homogenization, centrifugation and subsequent incubation steps were carried out at 4° C.

Aliquots of membrane fractions were incubated for 2 hours in duplicate with increasing concentrations of test compounds in the presence of 20 to 70 pM of [¹²⁵I]-buserelin (between 1000 and 2000 Ci/mmol depending on ligand batches). The assay was terminated by filtration under suction (Brandel 96-well harvester) through Whatman GF/B glass fiber filters. After repeated washes, filters were placed in counting vials with scintillation cocktail to measure the radioactivity of ¹²⁵I. For each experiment, curve-fitting of residual specific binding against concentrations of test compound gave the 50 % inhibitory concentration (IC₅₀). Each compound was tested in at least 4 experiments.

This LH-RH receptor assay was characterized by 4 saturation experiments using increasing concentration of [¹²⁵I]-buserelin in the absence or presence of 1 µM unlabelled buserelin for non specific binding determination. Specific binding data were analysed according to Scatchard's method. At equilibrium (2 hours of incubation), the dissociation constant (K_d) and the number of binding sites for [¹²⁵I]-buserelin were respectively equal to 88 ± 6 pM and 15.6 ± 2.9 pM.

For each test compound, the inhibitory constant (K_i) was calculated from its IC₅₀ according to the Cheng and Prusoff's equation : $K_i = IC_{50} / (1 + [radioligand] / K_d)$. K_i were then transformed into pK_i (= - log K_i) for final expression of affinity scales.

The natural ligand, LH-RH itself, displays a strong affinity with experimental IC₅₀ in the 10 nM range, i.e., a pK_i equal to about 8.

So-called superagonists like buserelin, leuporelin, tryptorelin, histrelin or deslorelin and antagonists like antide show an even stronger binding to LH-RH receptors with IC_{50} in the subnanomolar range, i.e. $pK_i > 9$.

The affinity of test peptides of the invention for the LH-RH receptors is given in

5 Table 1 below :

Table 1 : Affinity for LH-RH receptors

| Compound | pK_i (n) | Compound | pK_i (n) |
|------------|------------|-------------|------------|
| Example 1 | 8.83 (3) | Example 14 | 9.50 (3) |
| Example 2 | 9.61 (3) | Example 15 | 9.23 (3) |
| Example 3 | 9.57 (3) | Example 16 | 10.17 (3) |
| Example 4 | 10.01 (3) | Example 17 | 9.72 (3) |
| Example 5 | 8.86 (3) | Example 18 | 10.07 (3) |
| Example 6 | 9.33 (3) | Example 19 | 10.11 (3) |
| Example 7 | 8.20 (3) | LH-RH | 8.04 (4) |
| Example 8 | 8.73 (3) | Goserelin | 8.58 (4) |
| Example 9 | 8.63 (3) | Antide | 9.16 (12) |
| Example 10 | 9.64 (3) | Leuporelin | 9.33 (4) |
| Example 11 | 9.34 (3) | Buserelin | 9.35 (108) |
| Example 12 | 9.79 (4) | Tryptorelin | 9.85 (4) |
| Example 13 | 8.97 (3) | Deslorelin | 9.90 (4) |
| | | Histrelin | 9.98 (4) |

(n) : number of determinations

10 The peptides according to the general formula (IIa) exert an agonist activity upon the LH-RH receptors *in vivo*, resulting in the stimulation of LH secretion by the pituitary, which, in males, stimulates the secretion of testosterone by the testis.

Adult male Sprague-Dawley rats received a subcutaneous injection of various doses of LH-RH, tryptorelin or leuporelin, or their respective counterpart with Npg⁷ replacing Leu⁷ : example 1 ([Npg⁷]-LH-RH), example 6 ([Npg⁷]-leuporelin) or
 15 example 11 ([Npg⁷]-tryptorelin), dissolved in phosphate-buffered saline (PBS). Two hours later, blood samples were drawn for total plasma testosterone determination by

direct radioimmunoassay (Immunotech). Example 1 was a little more than twice as active as LH-RH itself, and the other compounds behaved like so-called « superagonists » by inducing a stronger stimulation of testosterone secretion at much lower doses (logarithmic x axis) than LH-RH (Figure 1; 8 animals per point). At 20
5 ng/kg, the secretion of testosterone was equally maximally stimulated by the four superagonists (exponential y axis scale), but at 10 ng/kg, examples 6 and 11 were a little more than twice as active as leuporelin and tryptorelin, respectively.

At this intermediate dose of 10 ng/kg, several examples with Npg⁷ or Ada⁷ in place of Leu⁷ according to the invention were screened for agonistic activity (Tables 2
10 and 3). When available from Bachem (France) or Sigma (France), the corresponding standard agonist with Leu⁷ was tested for comparison. In all the six instances, both Npg⁷- and Ada⁷- modified examples were more active, by a slight or wide margin depending on the Leu⁷ counterpart compound (Table 2). In two cases, the Ada⁷ replacement was more favorable than Npg⁷ (examples 27 and 28). Conversely, Npg⁷ led
15 to more potent agonists than Ada⁷ in two other structures (examples 6 and 11).

Those findings illustrate that increasing the overall hydrophobicity of the amino-acid in position 7 of LH-RH analogues is a general mean to achieve a greater potency *in vivo*. Depending on the rest of the molecule, other characteristics of the side chain in position 7, such as steric hindrance, modulate the resulting gain in activity.

20 An increase in hydrophobicity, as exemplified with Npg⁷, was compatible with several changes in positions 3 and 6 to give several agonists in a range of potency similar to that of leuporelin or tryptorelin (examples 5, 9, 13, 20, 21, 22 or 25 ; Tables 2 and 3). N-methylation of Npg⁷ was also compatible with a very strong agonistic activity (example 23 ; Table 3).

Table 2 : Stimulation of testosterone secretion

| Compound | Dose (ng/kg) | Total plasma testosterone (nmol/l) | n |
|---|-----------------|--|----|
| Vehicle (PBS) | - | 2.7 ± 0.3 | 46 |
| [D-Ala ⁶]-LH-RH | 10 | 6.4 ± 1.9* | 8 |
| Example 3 | 10 | 16.7 ± 1.9*** | 8 |
| [D-Ala ⁶ , Pro ⁹ NET]-LH-RH | 10 | 30.6 ± 7.2*** | 16 |
| Example 4 | 10 | 33.8 ± 5.8*** | 16 |
| Example 28 | 10 | 44.9 ± 6.0*** | 16 |
| [D-Phe ⁶ , Pro ⁹ NET]-LH-RH | 10 | 16.7 ± 4.3*** | 16 |
| Example 10 | 10 | 23.5 ± 4.0*** | 16 |
| Example 27 | 10 | 28.0 ± 4.1*** | 16 |
| Leuporelin | 10 | 33.5 ± 3.5*** | 22 |
| Example 6 | 10 | 48.6 ± 4.3*** | 22 |
| Example 29 | 10 | 36.2 ± 4.5*** | 16 |
| Tryptorelin | 10 | 20.3 ± 2.5*** | 22 |
| Example 11 | 10 | 30.8 ± 3.5*** | 22 |
| Example 30 | 10 | 24.8 ± 4.1*** | 15 |
| Deslorelin | 10 | 11.8 ± 3.5** | 6 |
| Example 12 | 10 | 20.5 ± 5.2*** | 6 |
| Example 5 | 10 | 21.2 ± 6.6** | 6 |
| Example 9 | 10 | 30.9 ± 3.6*** | 8 |
| Example 13 | 10 | 22.9 ± 4.2*** | 6 |

* p < 0.05 ; ** p < 0.01 ; *** p < 0.001 compared to vehicle alone

n : number of animals

22

TABLE 3 : Stimulation of testosterone secretion

| Compound | Dose (ng/kg) | Total plasma testosterone (nmol/l) | n |
|---------------|-----------------|--|----|
| Vehicle (PBS) | - | 4.3 ± 1.2 | 16 |
| Example 20 | 10 | 24.9 ± 5.0** | 8 |
| Example 21 | 10 | 32.4 ± 7.0** | 8 |
| Example 22 | 10 | 34.8 ± 4.5*** | 8 |
| Example 23 | 10 | 49.4 ± 4.6*** | 8 |
| Example 24 | 10 | 14.3 ± 4.3* | 8 |
| Example 25 | 10 | 27.3 ± 6.9** | 8 |
| Example 26 | 10 | 12.2 ± 2.7 | 8 |

5 * p < 0.05 ; ** p < 0.01 ; *** p < 0.001 compared to vehicle alone
n : number of animals

In conclusion, examples 6 and 23 on the one hand, and example 28 on the other hand, are the best examples to date of more potent LH-RH agonists than current therapeutic LH-RH analogues, obtained by increasing the hydrophobicity of the amino acid in position 7, respectively with Npg or Ada.

The peptides according to the general formula (IIb) exert an antagonistic activity upon the LH-RH receptors *in vivo*, resulting in the inhibition of ovulation in the female.

Adult female Wistar rats are first monitored for normal estrous cyclicity by daily vaginal smears. After at least 2 regular 4-day cycles, they received by subcutaneous injection either the vehicle alone (0.5 ml of a mixture of propylene-glycol and water : 20/80 vol/vol), or the LH-RH antagonist according to the formula (IIb) dissolved in this vehicle, around 2:00 PM on the day of proestrus. All but one vehicle-treated animals ovulated spontaneously as demonstrated by the recovery of numerous ovocytes in the oviducts the following morning.

20 When effective, LH-RH antagonists totally block ovulation. Antide, a commercially available standard LH-RH antagonist (from Bachem, France) showed a dose-related inhibition of ovulation (Table 4). Semi-logarithmic regression analysis gave a 50 % inhibitory dose (ID₅₀) equal to 0.99 µg/rat. When Leu⁷ was replaced by

23

Npg⁷ in the structure of antide (example 15), the inhibitory potency was markedly increased at 0.5 and 0.25 µg/rat, resulting in an ID₅₀ of 0.26 µg/rat. Variations in basic amino acids in positions 6 and 8 were compatible with Npg⁷ to give antagonists more potent than antide, as seen with the maximal or sub-maximal activity of examples 16, 17, 18 or 19 at the dose of 1 µg/rat (Table 4). Example 17 was especially active, but its effects were not related to the dose in the dose range studied. Therefore, introduction of an hydrophobic amino acid in position 7 is favorable to achieve stronger LH-RH antagonistic properties, as best exemplified to date by the 4-fold increase in the antioovulatory potency of antide by replacement of Leu⁷ by Npg⁷ (example 15).

10

Table 4 : inhibition of ovulation

| Treatment | Dose (µg/rat) | Number of ovulating females/total number of treated females | % of inhibition |
|--|------------------|--|-----------------|
| Vehicle | - | 38/39 | - |
| Antide | 10 | 0/8 | 100 % |
| | 5 | 0/11 | 100 % |
| | 2.5 | 2/6 | 67 % |
| | 1 | 5/16 | 69 % |
| | 0.5 | 4/5 | 20 % |
| [Npg ⁷]-antide (Example 15) | 1 | 1/5 | 80 % |
| | 0.5 | 0/5 | 100 % |
| | 0.25 | 4/10 | 60 % |
| | 0.1 | 5/5 | 0 % |
| Example 16 | 1 | 0/5 | 100 % |
| | 0.25 | 4/5 | 20 % |
| Example 17 | 1 | 0/12 | 100 % |
| | 0.75 | 0/7 | 100 % |
| | 0.5 | 4/7 | 43 % |
| | 0.25 | 1/5 | 80 % |
| Example 18 | 1 | 1/5 | 80 % |
| | 0.25 | 4/5 | 20 % |
| Example 19 | 1 | 0/5 | 100 % |
| | 0.25 | 3/5 | 40 % |

24

In conclusion of both agonistic and antagonistic studies *in vivo*, it has been shown that replacement of Leu⁷ by a more hydrophobic non aromatic amino acid, such as Npg or Ada, systematically increased the potency of existing analogues. Furthermore, closely
5 related analogues having an hydrophobic amino acid in position 7 without direct Leu⁷ counterpart for comparison, often displayed interesting levels of activity *per se*.

Therefore, the use of Npg, Ada or any other hydrophobic amino acid in position 7 of an LH-RH analogue sequence corresponding to the definition of general formula (I) is claimed as a general feature to obtain new LH-RH agonists or antagonists with high or
10 enhanced potency *in vivo*.

No sign of toxicity is observed with the peptides of the invention at pharmaceutically active doses.

Thus, the peptides of the invention and their pharmaceutically acceptable salts may be used in the treatment or prevention of various complaints or diseases wherein a
15 LH-RH agonist or antagonist activity is required.

The main target of LH-RH analogues is the pituitary gland, but direct actions have been reported on the gonads themselves (testis and ovary), on the thymus and some lymphoid cell lines, on mast cells and on breast, prostate or pancreatic tumors.

LH-RH agonists according to formula (IIa) exert on any LH-RH sensitive target,
20 either a stimulatory activity by short-term acute or pulsatile administrations, or an inhibitory effect by repeated or continuous administrations that induce the desensitization and the down-regulation of LH-RH receptors. In the case of the hypothalamo-pituitary-gonadal axis, prolonged administration results in a so-called "chemical" castration.

25 LH-RH antagonists according to formula (IIb) exert primarily an inhibitory effect on any LH-RH-sensitive target, but are also useful in obtaining or planning a rebound stimulatory release of LH and FSH when treatment is discontinued.

Due to this ambivalent potential of both LH-RH agonists and antagonists, all analogues according to formula (I) can find an appropriate therapeutic use in humans as
30 well as in animals, depending on doses, treatment regimens and routes of administration, in reproductive endocrinology and in the treatment or prevention of sex hormone-dependent benign or malignant tumors, alone or in combination with other

25

hormonal or antitumoral agents. LH-RH sensitive sex hormone-independent benign or malignant tumors can also regress upon treatment with LH-RH analogues according to formula (I), alone or in combination with antitumoral agents. Immune mechanisms can also be modified by LH-RH analogues according to formula (I), alone or in combination
5 with immuno-modulating or -suppressive agents such as glucocorticoids, cyclosporin, rapamycin, tacrolimus, their derivatives, and the like. The LH-RH analogues according to the invention are therefore very valuable in the treatment and prevention of autoimmune diseases, graft rejection or atopic diseases, and in the treatment of benign or malignant lymphoproliferative disorders.

10 LH-RH analogues according to formula (I) are especially useful, alone or in combination with sex steroids or gonadotrophins, in the inhibition, planning and triggering of ovulation in *in vitro* fertilization programs, and in the treatment of male and female infertility or hypogonadic states. Conversely, they can also be used in male or female contraception or treatment of hypergonadic states, alone or in combination
15 with sex steroids or gonadotrophins. This applies to men and women, but also to wild or domestic animals in uses such as improvement or control of reproductive performance, or as a tool to optimize breeding strategies.

LH-RH analogues according to formula (I) are also especially useful in men to treat advanced prostate cancer, but can also be used as a first line therapy in this
20 indication and in benign prostatic hypertrophy, alone or in combination with inhibitors of androgen action, i.e. antiandrogens such as cyproterone acetate, osaterone acetate, chlormadinone acetate, flutamide, nilutamide or bicalutamide and the like, or 5 α -reductase inhibitors such as finasteride, epristeride or turosteride and the like, or C₁₇₋₂₀ lyase inhibitors such as abiraterone and the like.

25 LH-RH analogues according to formula (I) are also especially useful in the treatment or prevention of breast cancer in women and in men, especially estrogen receptor positive tumors, alone or in combination with antiestrogens such as tamoxifen, raloxifen or droloxifen and the like, or with aromatase inhibitors such as atamestane, formestane, letrozole, anastrozole and the like, or with C₁₇₋₂₀ lyase inhibitors such as
30 abiraterone and the like, but also of certain estrogen receptor negative tumors that respond to the direct effects of LH-RH analogues or indirectly to their gonadal suppressive activity.

26

Other gynecological conditions, such as endometrial hyperplasia, leiomyoma, adenomyoma, endometriosis, polycystic ovary syndrome, hirsutism and benign breast disease (pain, cysts or fibrosis), can also be prevented by or benefit from treatment with the LH-RH analogues according to formula (I), alone or in combination with antiestrogens (cited above), progestins such as cyproterone acetate, osaterone acetate, chlormadinone acetate, norgestrol acetate, promegestone, demegestone, trimegestone and the like, or their contraceptive or post-menopausal replacement combination formulations with estrogens such as estradiol or ethynylestradiol. The peptides of the invention can also interfere with gestation by inducing abortion or by triggering labor, alone or in combination with estrogens (cited above), antiprogestins such as mifepristone or prostaglandin analogs such as sulprostone.

Similar indications can be encountered in veterinary medicine for male or female domestic or wild animals that may require the use of LH-RH analogues according to formula (I).

Another aspect of the present invention is therefore pharmaceutical compositions containing an effective amount of at least one peptide of formula (I) or a pharmaceutically acceptable salt thereof, alone or mixed with suitable pharmaceutical excipients.

A further aspect of the invention relates to a method of treating and/or preventing the above diseases which comprises administering to patients or animals in need thereof a therapeutically effective amount of a peptide of formula (I) or a pharmaceutically acceptable salt thereof.

A further aspect of the invention relates to the use of the peptides of formula (IIa), or of their pharmaceutically acceptable salts, for the preparation of a medicament having LH-RH agonist activity. Also within the scope of the invention is the use of the peptides of formula (IIb), or of their pharmaceutically acceptable salts, for the preparation of a medicament having LH-RH antagonist activity.

The peptides of the invention are preferentially administered by parenteral administration, although oral formulations are also effective provided that the dosage is appropriately increased.

Preferred delivery systems for LH-RH agonists of formula (IIa) in long term pituitary-gonadal suppressive indications are slow-release implantable devices, or

27

injectable biodegradable polymeric micro- or nano-particles or
-capsules, or micro- or nano-emulsions, with unit doses of the peptides or of their
appropriate salts ranging from 1 mg to 100 mg per human patient for a duration of
action ranging from 1 month to 1 year. Long term administration of LH-RH antagonists
5 of formula (IIb) will generally require higher dosages in the same slow-release
formulations, ranging from 10 mg to 1 g for 1 week to 1 year of activity. Animal doses
will be adapted on a body weight basis depending on the wild or domestic species to be
treated either by LH-RH agonists or antagonists according to formula (I).

All other means of parenteral administration are suited for immediate, delayed or
10 planned delivery of the peptides of the invention : subcutaneous, intramuscular,
intravenous, intragonadal or intratumoral needle bolus injections, or prolonged
continuous, pulsatile or planned perfusions or microinfusions using the appropriate
pump technology ; gas-propelled subcutaneous microinjection ; vaginal creams, gels or
pessaries ; rectal enemas or suppositories ; transdermal creams, gels, lotions, solutions,
15 patches or iontophoretic devices ; nasal spray or dry powder inhalation device ;
ophthalmic solutions, gels, creams or contact lenses ; pulmonary inhalation of micro- or
nano-particles or droplets generated manually or with an appropriate pulverization or
nebulization device.

The unit dose of these parenteral administrations will range in humans from 0.001
20 mg to 10 mg/day for LH-RH agonists of formula (IIa) and from 0.01 to 100 mg/day for
LH-RH antagonists of formula (IIb), one to 16 times per day (in the case of pulsatile
administration).

Oral administration of peptides according to the invention is preferentially
effected using gastro-resistant and delayed enteric or colonic release formulations which
25 can be coated pills or tablets containing two or more components, hardened gelatin
capules, special polymeric macro-, micro- or nano-beads containing them, or any device
designed to protect them from gastrointestinal degradation and to release them when
needed. All other formulations to be taken orally such as solutions, suspensions, syrups,
gels and the like, or lingual, sublingual or chewable formulations are suited provided
30 that the dosage is increased.

Overall, effective oral treatment may be achieved with any of the above formulations with unit doses of peptides of formula (I) ranging from 1 mg to 1 g per human patient, from one to 16 times per day (in the case of pulsatile administration).

5 All the above-mentioned oral or parenteral formulations of the peptides according to the invention and their pharmaceutical acceptable salts may contain one or several pharmaceutically appropriate excipients, one or several inhibitors of proteases, and one or several absorption enhancers as needed by the specific route of administration.

Raw powder of pure peptides according to the invention or their pharmaceutically acceptable salts can also be used, especially in the lyophilized form for fast sublingual application.

The invention will now be described with reference to the following examples, which are not intended to limit the invention in any respect. In these examples, the starting materials used were either commercially available or synthesized, as mentioned below :

15 - Fmoc-Glu-OH, Fmoc-Tyr(OBut)-OH, Fmoc-Trp-OH and Fmoc-His(Trt) were purchased from Propeptide (France).

- Fmoc- β -Nal-OH and Fmoc-pClPhe were synthesized as racemates. These amino acids and their corresponding acetyl ethylesters were enzymatically resolved using subtilisin (5) ;

20 - Other Fmoc protected amino-acids were purchased from Bachem (Switzerland), Novabiochem (Switzerland), American Peptide C^o (USA) or Neosystem (France).

- Adamantylalanine was synthesized as described by Kim Quang Do et al (6).

EXAMPLE 1 : pGlu-His-Trp-Ser-Tyr-Gly-Npg-Arg-Pro-Gly-NH₂

Example 1 was synthesized on a Rink resin using a Fmoc strategy as mentioned above in the general synthesis of the invention peptides. Cleavage was carried out with TFA in the presence of scavengers.

Purification was carried out using a linear gradient of from 10 to 40 % of eluent B (CH₃CN/0.1 % TFA 60/40 v/v) over 30 min.

68 mg (approximate yield 24 %) of purified material were obtained.

30 Mass spectral analysis - ES⁺ mode :

expected : 1195.3

found : 1195.7.

21

net peptide content 73.9 % ; purity 97.2 % ; retention time 16.4 min.

EXAMPLE 2 : pGlu-His-Trp-Ser-Tyr-Gly-Npg-Arg-Pro-NEt

The synthesis was carried out on Boc-Pro-PAM resin. The second amino acid, arginine, was also incorporated via a Boc strategy. The subsequent amino acids were incorporated via a Fmoc strategy. After coupling of the N-terminal amino acid, the peptide was cleaved from the resin and converted into ethylamide by aminolysis using ethylamine (5 ml of ethylamine per gram of peptide resin for 20 hours, -78°C).

After cleavage the protected peptide was extracted with methanol, dried and deprotected with HF as described.

10 Purification was carried out using a linear gradient of from 10 to 60 % of eluent B over 30 min. 15 mg (approximate yield 8 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1166.3

found : 1166.8.

15 net peptide content 72.7 % ; purity 95.0 % ; retention time 15.1 min.

EXAMPLE 3 : pGlu-His-Trp-Ser-Tyr-D-Ala-Npg-Arg-Pro-Gly-NH₂

Assembling and cleavage of the peptide were carried out as described for Example

1.

Purification was carried out using a linear gradient of from 10 to 50 % of eluent B over 30 min.

66 mg (approximate yield 27 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1209.4

found : 1209.5.

25 net peptide content 72.6 % ; purity 95.2 % ; retention time 14.5 min.

EXAMPLE 4 : pGlu-His-Trp-Ser-Tyr-D-Ala-Npg-Arg-Pro-NEt

Assembling and cleavage of the peptide were carried out as described for Example

2.

Purification was carried out using a linear gradient of from 10 to 60 % of eluent B over 30 min.

8 mg (approximate yield 7 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1180.3

found : 1181.0

net peptide content 69.5 % ; purity 96.9 % ; retention time 17.7 min.

EXAMPLE 5 : pGlu-His-Trp-Ser-Tyr-D-Leu-Npg-Arg-Pro-Gly-NH₂

5 Assembling and cleavage of the peptide were carried out as described for Example

1.

Purification was carried out using a linear gradient of from 15 to 50 % of eluent B over 30 min.

123 mg (approximate yield 36 %) of purified material were obtained.

10 Mass spectral analysis - ES⁺ mode :

expected : 1251.4

found : 1251.9

net peptide content 71.7 % ; purity 95.7 % ; retention time 13.9 min.

EXAMPLE 6 : pGlu-His-Trp-Ser-Tyr-D-Leu-Npg-Arg-Pro-NEt

15 Assembling and cleavage of the peptide were carried out as described for Example

2.

Purification was carried out in two steps, the first one using a linear gradient of from 15 to 50 % of eluent B over 30 min., and the second one using a linear gradient of from 15 to 40 % of eluent B over 30 min.

20 49 mg (approximate yield 20 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1222.4

found : 1223.6 (MH⁺)

net peptide content 73.6 % ; purity 95.3 % ; retention time 14.6 min.

25 EXAMPLE 7 : pGlu-His-Trp-Ser-Tyr-D-Npg-Npg-Arg-Pro-Gly-NH₂

Assembling and cleavage of the peptide were carried out as described for Example

1.

Purification was carried out in two steps, the first one using a linear gradient of from 30 to 60 % of eluent B over 30 min., and the second one using a linear gradient of from 25 to 60 % of eluent B over 30 min.

13 mg (approximate yield 4 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1265.5

found 1266.0

net peptide content 71.1 % ; purity 97.8 % ; retention time 15.1 min.

EXAMPLE 8 : pGlu-His-Trp-Ser-Tyr-D-Npg-Npg-Arg-Pro-NEt

5 Assembling and cleavage of the peptide were carried out as described for Example
2.

Purification was carried out using a linear gradient of from 20 to 80 % of eluent B
over 30 min.

13 mg (approximate yield 4 %) of purified material were obtained.

10 Mass spectral analysis - ES⁺ mode :

expected : 1236.4

found : 1237.5 (MH⁺)

net peptide content 68.5 % ; purity 96.2 % ; retention time 13.9 min.

15 EXAMPLE 9 : pGlu-His-Trp-Ser-Tyr-D-Phe-Npg-Arg-Pro-Gly-NH₂

The synthesis was carried out as described for example 1.

Purification was carried out using a linear gradient of from 25 to 80 % of eluent B
over 30 min.

61 mg (approximate yield 16 %) of purified material were obtained.

20 Mass spectral analysis - ES⁺ mode :

expected : 1285.5

found : 1286.2 (MH⁺)

net peptide content 71.8 % ; purity 96.8 % ; retention time 14.9 min.

EXAMPLE 10 : pGlu-His-Trp-Ser-Tyr-D-Phe-Npg-Arg-Pro-NEt

25 Assembling and cleavage of the peptide were carried out as described for example
2.

Purification was carried out using a linear gradient of from 20 to 80 % of eluent B
over 30 min.

6 mg (approximate yield 4 %) of purified material were obtained.

30 Mass spectral analysis - ES⁺ mode :

expected : 1256.4

found : 1257.4 (MH⁺)

net peptide content 63.2 % ; purity 96.9 % ; retention time 13.9 min.

EXAMPLE 11 : pGlu-His-Trp-Ser-Tyr-D-Trp-Npg-Arg-Pro-Gly-NH₂

Assembling and cleavage of the peptide were carried out as described for example

1.

5 Purification was carried out using a linear gradient of from 20 to 80 % of eluent B over 30 min.

22 mg (approximate yield 7 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1324.5

10 found : 1325.5 (MH⁺)

net peptide content 71.6 % ; purity 97.1 % ; retention time 13.1 min.

EXAMPLE 12 : pGlu-His-Trp-Ser-Tyr-D-Trp-Npg-Arg-Pro-NEt

Assembling and cleavage of the peptide were carried out as described for example

2.

15 Purification was carried out using a linear gradient of from 20 to 80 % of eluent B over 30 min.

10 mg (approximate yield 5 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1295.4

20 found : 1296.3 (MH⁺)

net peptide content 71.3 % ; purity 98.4 % ; retention time 13.8 min.

EXAMPLE 13 : pGlu-His-Trp-Ser-Tyr-D-Nal-Npg-Arg-Pro-Gly-NH₂

Assembling and cleavage of the peptide were carried out as described for example

1.

25 Purification was carried out using a linear gradient of from 15 to 75 % of eluent B over 30 min.

205 mg (approximate yield 50 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1335.6

30 found : 1336.2 (MH⁺)

net peptide content 74.8 % ; purity 95.6 % ; retention time 14.9 min.

EXAMPLE 14 : pGlu-His-Trp-Ser-Tyr-D-Nal-Npg-Arg-Pro-NEt

33

Assembling and cleavage were carried out as described for example 2.

Purification was carried out using a linear gradient of from 25 to 50 % of eluent B over 30 min.

82 mg (approximate yield 22 %) of purified material were obtained.

5 Mass spectral analysis - ES⁺ mode :

expected : 1306.5

found : 1307.2 (MH⁺)

net peptide content 76.0 % ; purity 97.4 % ; retention time 15.8 min.

EXAMPLE 15 : AcD-Nal-D-pClPhe-D-Pal-Ser-NicLys-D-NicLys-Npg-IprLys-

10 Pro-D-Ala-NH₂

The synthesis was carried out on a 4-methylbenzhydrylamine resin.

D-alanine and proline were introduced using a Boc strategy as described above for the general synthesis of the invention peptides. The other amino acids were incorporated via a Fmoc strategy as described above.

15 The synthesis was started with Boc-D-Ala-OH.

The peptides were deprotected and cleaved from the resin using HF as described above.

Purification was carried out using a linear gradient of from 15 to 70 % of eluent B over 30 min.

20 49 mg (approximate yield 31 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1605.3

found : 1605.5

net peptide content 67.6 % ; purity 98.3 % ; retention time 15.5 min.

25 EXAMPLE 16 : AcD-Nal-D-pClPhe-D-Pal-Ser-Tyr-D-Cit-Npg-Arg-Pro-D-Ala-NH₂

Assembling and cleavage of the peptide were carried out as described for example 15, arginine being introduced using a Boc strategy.

30 Purification was carried out using a linear gradient of from 30 to 60 % of eluent B over 30 min.

16 mg (approximate yield 9 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

34

expected : 1444.9

found : 1444.6

net peptide content 67.1 % ; purity 97.0 % ; retention time 16.8 min.

EXAMPLE 17 : AcD-Nal-D-pClPhe-D-Pal-Ser-Tyr-D-Cit-Npg-IprLys-Pro-D-

5 Ala-NH₂

Assembling and cleavage of the peptide were carried out as described for Example 15.

Purification was carried out using a linear gradient of from 10 to 60 % of eluent B over 30 min.

10 55 mg (approximate yield 29 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected value : 1459.9

found : 1459.3

net peptide content 69.8 % ; purity : 96.4 % ; retention time 11.2 min.

15 EXAMPLE 18 : AcD-Nal-D-pClPhe-D-Pal-Ser-Tyr-D-HCit-Npg-IprLys-Pro-D-

Ala-NH₂

Assembling and cleavage of the peptide were carried out as described for example 15.

20 Purification was carried out using a linear gradient of from 30 to 50 % of eluent B over 30 min.

40 mg (approximate yield 17 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1473.2

found : 1473.2

25 net peptide content 69.8 % ; purity 95.7 % ; retention time 15.9 min.

EXAMPLE 19 : AcD-Nal-D-pClPhe-D-Pal-Ser-Tyr-D-HCit-Npg-Arg-Pro-D-Ala-

NH₂

Assembling and cleavage of the peptide were carried out described for example 16.

30 Purification was carried out using a linear gradient of from 30 to 60 % of eluent B over 30 min.

55 mg (approximate yield 21 %) of purified material were obtained.

35

Mass spectral analysis - ES⁺ mode :

expected : 1459.1

found : 1459.2

net peptide content 68.2 % ; purity 96.6 % ; retention time 15.7 min.

5 EXAMPLE 20 : pGlu-His-Trp-Ser-Tyr-D-Pal-Npg-Arg-Pro-Gly-NH₂

Assembling and cleavage of the peptide were carried out as described for Example

1.

Purification was carried out using a linear gradient of from 5 to 50 % of eluent B over 30 min.

10 74 mg (approximate yield 29 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1287.3

found : 1287.3

net peptide content 72.1 % ; purity 98.6 % ; retention time 12.5 min.

15 EXAMPLE 21 : pGlu-His-Trp-Ser-Tyr-D-4Pal-Npg-Arg-Pro-Gly-NH₂

Assembling and cleavage of the peptide were carried out as described for Example

1.

Purification was carried out using a linear gradient of from 10 to 30 % of eluent B over 30 min.

20 7 mg of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1287.3

found : 1287.2

net peptide content 64.3 % ; purity 98.4 % ; retention time 12.2 min.

25 EXAMPLE 22 : pGlu-His-Trp-Ser-Tyr-D-HPhe-Npg-Arg-Pro-Gly-NH₂

Assembling and cleavage of the peptide were carried out as described for Example

1.

Purification was carried out using a linear gradient of from 15 to 70 % of eluent B over 30 min.

30 94 mg (approximative yield 36 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1300.3

found : 1300.2

net peptide content 74.2 % ; purity 97.5 % ; retention time 15.5 min.

EXAMPLE 23 : pGlu-His-Trp-Ser-Tyr-D-Leu-MeNpg-Arg-Pro-NEt

Assembling and cleavage of the peptide were carried out as described for Example

5 2.

Purification was carried out using a linear gradient of from 20 to 80 % of eluent B over 30 min.

50 mg (approximate yield 17 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

10 expected : 1237.5

found : 1237.4

net peptide content 73.7 % ; purity 95.0 % ; retention time 16.2 min.

EXAMPLE 24 : pGlu-His-1Nal-Ser-Tyr-D-Leu-Npg-Arg-Pro-NEt

Assembling and cleavage of the peptide were carried out as described for Example

15 2.

Purification was carried out using a linear gradient of from 10 to 70 % of eluent B over 30 min.

68 mg (approximate yield 7 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

20 expected : 1234.5

found : 1234.2

net peptide content 73.3 % ; purity 98.5 % ; retention time 15.5 min.

EXAMPLE 25 : pGlu-His-2Nal-Ser-Tyr-D-Leu-Npg-Arg-Pro-NEt

Assembling and cleavage of the peptide were carried out described for example 2.

25 Purification was carried out using a linear gradient of from 10 to 65 % of eluent B over 30 min.

17 mg (approximate yield 7 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1234.5

30 found : 1234.2

net peptide content 71.5 % ; purity 98.0 % ; retention time 14.0 min.

EXAMPLE 26 : pGlu-His-Bal-Ser-Tyr-D-Leu-Npg-Arg-Pro-NEt

37

Assembling and cleavage of the peptide were carried out as described for Example

2.

Purification was carried out using a linear gradient of from 20 to 70 % of eluent B over 30 min.

5 41 mg (approximate yield 16 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1240.5

found : 1240.4

net peptide content 89.0 % ; purity 97.4 % ; retention time 15.6 min.

10 EXAMPLE 27 : pGlu-His-Trp-Ser-Tyr-D-Phe-Ada-Arg-Pro-NEt

Assembling and cleavage of the peptide were carried out as described for Example

2.

Purification was carried out using a linear gradient of from 15 to 50 % of Eluent B over 30 min.

15 90 mg (approximate yield 14 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1335.6

found : 1335.5

net peptide content 76.3 % ; purity 97.8 % ; retention time 17.0 min.

20 EXAMPLE 28 : pGlu-His-Trp-Ser-Tyr-D-Ala-Ada-Arg-Pro-NEt

Assembling and cleavage of the peptide were carried out as described for Example

2.

Purification was carried out using a linear gradient of from 15 to 50 % of eluent B over 30 min.

25 150 mg (approximate yield 24 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1259.5

found : 1259.0

net peptide content 72.9 % ; purity 97.4 % ; retention time 14.1 min.

30 EXAMPLE 29 : pGlu-His-Trp-Ser-Tyr-D-Leu-Ada-Arg-Pro-NEt

Assembling and cleavage of the peptide were carried out as described for Example

2.

Purification was carried out using a linear gradient of from 15 to 70 % of eluent B over 30 min.

100 mg (approximate yield 15 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

5 expected : 1301.6

found : 1301.5

net peptide content 72.7 % ; purity 97.3 % ; retention time 17.7 min.

EXAMPLE 30 : pGlu-His-Trp-Ser-Tyr-D-Trp-Ada-Arg-Pro-Gly-NH₂

Assembling and cleavage of the peptide were carried out as described for Example

10 1.

Purification was carried out using a linear gradient of from 15 to 70 % of eluent B over 30 min.

30 mg (approximate yield 11 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

15 expected : 1403.6

found : 1403.2

net peptide content 82.9 % ; purity 95.0 % ; retention time 16.0 min.

REFERENCES

- (1) G. BARANY and R.B. MERRIFIELD (1979)
5 The Peptides, Analysis, Synthesis, Biology, Vol. 2, Chapter 1.
- (2) E. ATHERTON and R.C. SHEPPARD (1989)
Solid phase peptide synthesis, IRL Press, OXFORD
- (3) D. Le NGUEN, A. HEITZ and B. CASTRO (1987)
J. Chem. Soc. Perkin Trans. I, 1915
- 10 (4) E. KAISER, R.L. COLESCOTT, C.D. BOSSINGER and P.I. COOK (1970)
Anal. Biochem., 34, 595
- (5) P.N. RAO, J.E. BURDETT Jr, J.W. CESSAD, C.M. DI NUNNO,
D.M. PETERSON and H.K. KIM (1987)
Int. J. Pept. Protein Res., 29, 118
- 15 (6) KIM QUANG DO, P. THANEI, M. CAVIEZEL and R. SCHWYZER (1979)
Helvetica Chimica Acta, 62, 956-964

40

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: Laboratoire Theramex
- (B) STREET: 6, Avenue du Prince Héréditaire Albert
- (C) CITY: Monaco
- (E) COUNTRY: Monaco
- (F) POSTAL CODE (ZIP): 98000
- (G) TELEPHONE: 377 92 05 08 08
- (H) TELEFAX: 377 92 05 70 00

(ii) TITLE OF INVENTION: LH-RH peptide analogues, their uses and pharmaceutical compositions containing them.

(iii) NUMBER OF SEQUENCES: 8

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa is pGlu ; D-pGlu ; Sar ; AcSar ; Pro ; AcPro ; ForPro ; OH-Pro ; Ac-OH-Pro ; dehydro-Pro ; Ac-dehydro-Pro ; Ser ; D- Ser ; Ac-D-Ser ; Thr ; D-Thr ; Ac-D-Thr ; or an optionally acylated aromatic D-amino acid"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:2
- (D) OTHER INFORMATION:/note= "Xaa is a direct bond ; His ; or an aromatic D-amino acid"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:3
- (D) OTHER INFORMATION:/note= "Xaa is an aromatic L- or D-amino acid"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site

41

(B) LOCATION:4

(D) OTHER INFORMATION:/note= "Xaa is Ala, Ser, D-Ser, MeSer, Ser(OBu^t), Ser(OBzl) or Thr"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:5

(D) OTHER INFORMATION:/note= "Xaa is an aromatic L-amino acid or a basic L- or D-amino acid"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:6

(D) OTHER INFORMATION:/note= "Xaa is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu^t) ; D-Asp(OBu^t) ; D-Glu(OBu^t) ; D-Thr(OBu^t) ; D-Cys(OBu^t) ; D-Ser(OR₁) where R₁ is a sugar moiety ; an aza-amino acid; D-His which may be substituted on the imidazole ring by a (C₁-C₆)alkyl or by a (C₂-C₇)acyl group ; an aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl side chain ; an aromatic D-amino acid ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic L- or D-amino acid"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:7

(D) OTHER INFORMATION:/note= " Xaa is a non-aromatic hydrophobic amino acid with 5 to 20 carbon atoms"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:8

(D) OTHER INFORMATION:/note= "Xaa is a basic L- or D-amino acid"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:10

(D) OTHER INFORMATION:/note= "Xaa is GlyNH₂ ; D-AlaNH₂ ; azaGlyNH₂ ; or a group -NHR₂ where R₂ is an optionally substituted (C₁-C₄)alkyl "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

| | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Pro | Xaa |
| 1 | | | | 5 | | | | | 10 |

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

42

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa is pGlu, Sar or AcSar"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:2
- (D) OTHER INFORMATION:/note= "Xaa is His"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:3,4,7
- (D) OTHER INFORMATION:/note= "Xaa is as defined for SEQ ID

NO:1"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:5
- (D) OTHER INFORMATION:/note= "Xaa is an aromatic L-amino

acid"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:6
- (D) OTHER INFORMATION:/note= "Xaa is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu^t) ; D-Asp(OBu^t) ; D-Glu(OBu^t) ; D-Thr(OBu^t) ; D-Cys(OBu^t) ; D-Ser(OR₁) where R₁ is a sugar moiety ; an aza-amino acid; D-His which may be substituted on the imidazole ring by a (C₁-C₆)alkyl or by a (C₂-C₇)acyl group ; an aliphatic D-amino acid with a (C₁-C₆)alkyl or a (C₃-C₆)cycloalkyl side chain ; an aromatic D-amino acid ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic D-amino acid"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:8
- (D) OTHER INFORMATION:/note= "Xaa is a basic L-amino acid"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:10
- (D) OTHER INFORMATION:/note= "Xaa is GlyNH₂, azaGlyNH₂ or a group -NHR₂ where R₂ is as defined for SEQ ID NO:1"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Pro Xaa
 1 5 10

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

43

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:1,3,4,5,7,8

(D) OTHER INFORMATION:/note= "Xaa is as defined for SEQ ID NO:1"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:2

(D) OTHER INFORMATION:/note= "Xaa is a direct bond or an aromatic D-amino acid"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:6

(D) OTHER INFORMATION:/note= "Xaa is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu^t) ; D-Asp(OBu^t) ; D-Glu(O-Bu^t) ; D-Thr(O-Bu^t) ; D-Cys(O-Bu^t) ; D-Ser(O-R₁) where R₁ is a sugar moiety ; an aliphatic D-amino acid with a (C₁-C₆)alkyl or a (C₃-C₆)cycloalkyl side chain ; an aromatic D-amino acid ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic L- or D-amino acid"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:10

(D) OTHER INFORMATION:/note= "Xaa is GlyNH₂ or D-AlaNH₂"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

| | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Pro | Xaa |
| 1 | | | | 5 | | | | | 10 |

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Modified-sites

(B) LOCATION:1

(D) OTHER INFORMATION:/note= "Xaa is pGlu"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:3,7

(D) OTHER INFORMATION:/note= "Xaa is as defined for SEQ ID NO:2"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

44

(B) LOCATION: 6

(D) OTHER INFORMATION:/note= "Xaa is Gly ; an aliphatic D-amino acid with a (C₁-C₆)alkyl side chain ; or an aromatic D-amino acid"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:10

(D) OTHER INFORMATION:/note= "Xaa is GlyNH₂ or a group - NHC₂H₅"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Xaa His Xaa Ser Tyr Xaa Xaa Arg Pro Xaa
1 5 10

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Modified-sites

(B) LOCATION:1

(D) OTHER INFORMATION:/note= "Xaa is Ac-D-Nal"

(ix) FEATURE:

(A) NAME/KEY: Modified-sites

(B) LOCATION:2

(D) OTHER INFORMATION:/note= "Xaa is D-pClPhe"

(ix) FEATURE:

(A) NAME/KEY: Modified-sites

(B) LOCATION:3

(D) OTHER INFORMATION:/note= "Xaa is D-Pal"

(ix) FEATURE:

(A) NAME/KEY: Modified-sites

(B) LOCATION:5,7,8

(D) OTHER INFORMATION:/note= "Xaa is as defined for SEQ ID

NO:3"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:6

(D) OTHER INFORMATION:/note= "Xaa is Gly or a basic L- or D-amino acid"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:10

(D) OTHER INFORMATION:/note= "Xaa is D-AlaNH₂"

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Xaa Xaa Xaa Ser Xaa Xaa Xaa Xaa Pro Xaa
1 5 10

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1,2,3,4,5,6,8,10

(D) OTHER INFORMATION:/note= "Xaa is as defined for SEQ ID NO:1"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 7

(D) OTHER INFORMATION:/note= " Npg may be N-alpha-substituted by a (C₁-C₄)alkyl group which may be substituted by one or several fluorine atoms"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Xaa Xaa Xaa Xaa Xaa Xaa Npg Xaa Pro Xaa
1 5 10

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1,2,3,4,5,6,8,10

(D) OTHER INFORMATION:/note= "Xaa is as defined for SEQ ID NO:2"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 7

(D) OTHER INFORMATION:/note= " Npg may be N-alpha-substituted by a (C₁-C₄)alkyl group which may be substituted by one or several fluorine atoms"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Xaa Xaa Xaa Xaa Xaa Xaa Npg Xaa Pro Xaa

46

1 5 10

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1,2,3,4,5,6,8,10
- (D) OTHER INFORMATION:/note= "Xaa is as defined for SEQ ID

NO:3"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 7
- (D) OTHER INFORMATION:/note= " Npg may be N-alpha-substituted by a (C₁-C₄)alkyl group which may be substituted by one or several fluorine atoms"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Xaa Xaa Xaa Xaa Xaa Xaa Npg Xaa Pro Xaa
1 5 10

47

CLAIMS

1. A LH-RH peptide analogue, in which a non-aromatic hydrophobic amino acid
5 having from 7 to 20 carbon atoms is substituted for Leu⁷; and its pharmaceutically acceptable salts.
2. A peptide analogue according to claim 1, of the formula (SEQ ID N° : 1) :
A1-A2-A3 -A4-A5-A6-HAA-A7-Pro-Z (I)
in which :
10 - A1 is pGlu ; D-pGlu ; Sar ; AcSar ; Pro ; AcPro ; ForPro ; OH-Pro ; Ac-OH-Pro ;
dehydro-Pro ; Ac-dehydro-Pro ; Ser ; D-Ser ; Ac-D-Ser ; Thr ; D-Thr ; Ac-D-Thr ; or an
aromatic D-amino acid which may be acylated;
- A2 is a direct bond ; His ; or an aromatic D-amino acid;
- A3 is an aromatic L- or D-amino acid;
15 - A4 is Ala, Ser, D-Ser, MeSer, Ser(OBu¹), Ser(OBzl) or Thr;
- A5 is an aromatic L-amino acid or a basic L- or D-amino acid;
- A6 is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-
Et)Pen ; D-Ser(OBu¹) ; D-Asp(OBu¹) ; D-Glu(OBu¹) ; D-Thr(OBu¹) ; D-Cys(OBu¹) ; D-
Ser(OR₁) where R₁ is a sugar moiety ; an aza-amino acid; D-His which may be
20 substituted on the imidazole ring by a (C₁-C₆)alkyl or by a (C₂-C₇)acyl group ; an
aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl side chain ; an
aromatic D-amino acid ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-
perhydrodiphenyl-Ala ; or a basic L- or D-amino acid;
- HAA is a non-aromatic hydrophobic amino acid having from 7 to 20 carbon atoms ;
25 - A7 is a basic L- or D-amino acid;
- Z is GlyNH₂ ; D-AlaNH₂ ; azaGlyNH₂ ; or a group -NHR₂ where R₂ is a (C₁-C₄)alkyl
which may be substituted by an hydroxy or one or several fluorine atoms, a (C₃-
C₆)cycloalkyl or a heterocyclic radical selected from morpholinyl, pyrrolidinyl and
piperidyl;
30 and its pharmaceutically acceptable salts.

3. A peptide analogue according to claim 2, of the formula (SEQ ID N° : 2) :



in which :

- A1 is pGlu, Sar or AcSar;
 - A2 is His;
 - A3 and A4 are as defined for (I) in claim 2;
 - A5 is an aromatic L-amino acid;
 - 5 - A6 is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu¹) ; D-Asp(OBu¹) ; D-Glu(OBu¹) ; D-Thr(OBu¹) ; D-Cys(OBu¹) ; D-Ser(OR₁) where R₁ is a sugar moiety ; an aza-amino acid; D-His which may be substituted on the imidazole ring by a (C₁-C₆)alkyl or by a (C₂-C₇)acyl group ; an aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl side chain ; an
 - 10 aromatic D-amino acid ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic D-amino acid;
 - HAA is as defined for (I) in claim 2;
 - A7 is a basic L-amino acid;
 - Z is GlyNH₂, azaGlyNH₂ or a group -NHR₂ where R₂ is as defined for (I) in claim 2;
 - 15 and its pharmaceutically acceptable salts.
4. A peptide analogue according to 3, of the formula (SEQ ID N° : 4) :
- pGlu-His-A3-Ser-Tyr-A6-HAA-Arg-Pro-Z (IIIa)
- in which :
- A3 and HAA are as defined for (IIa) in claim 3 ;
 - 20 - A6 is Gly ; and aliphatic D-amino acid with a (C₁-C₈)alkyl side chain ; or an aromatic D-amino acid ;
 - Z is Gly or a group -NHC₂H₅ ;
 - and its pharmaceutically acceptable salts.
5. A peptide analogue according to claim 4 wherein A3 is Trp ;
- 25 and its pharmaceutically acceptable salts.
6. A peptide analogue according to one of claims 3 to 5 wherein HAA is Ada or Npg where Npg may be N-alpha substituted by a (C₁-C₄)alkyl group which may be substituted by one or several fluorine atoms ;
- and its pharmaceutically acceptable salts.
- 30 7. A peptide analogue according to claim 6 wherein HAA is Npg where Npg may be N-alpha substituted by a (C₁-C₄)alkyl group which may be substituted by one or several fluorine atoms ;

and its pharmaceutically acceptable salts.

8. A peptide analogue according to claim 7 wherein HAA is Npg which may be N-alpha-methylated ;

and its pharmaceutically acceptable salts.

5 9. A peptide analogue according to claim 2, of the formula (SEQ ID N° : 3) :



in which :

- A1 as defined for (I) in claim 2;

- A2 is a direct bond or an aromatic D-amino acid;

10 - A3, A4 and A5 are as defined for (I) in claim 2;

- A6 is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu¹) ; D-Asp(OBu¹) ; D-Glu(O-Bu¹) ; D-Thr(O-Bu¹) ; D-Cys(O-Bu¹) ; D-Ser(O-R₁) where R₁ is a sugar moiety ; an aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl side chain ; an aromatic D-amino acid ; D-cyclohexadienyl-Gly ;

15 D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic L- or D-amino acid;

- HAA and A7 are as defined for (I) in claim 2;

- Z is GlyNH₂ or D-AlaNH₂;

and its pharmaceutically acceptable salts.

10. A peptide analogue according to claim 9, of the formula (SEQ ID N° : 5) :



in which:

- A5 is as defined for (IIb) in claim 9;

- A6 is Gly or a basic L- or D- amino acid;

- HAA and A7 are as defined for (IIb) in claim 9;

25 and its pharmaceutically acceptable salts.

11. A peptide analogue according to claim 9 or 10 wherein HAA is Ada or Npg where Npg may be N-alpha substituted by a (C₁-C₄)alkyl group which may be substituted by one or several fluorine atoms ;

and its pharmaceutically acceptable salts.

30 12. A peptide analogue according to claim 11 wherein HAA is Npg where Npg may be N-alpha substituted by a (C₁-C₄)alkyl group which may be substituted by one or several fluorine atoms ;

and its pharmaceutically acceptable salts.

13. A peptide analogue according to claim 12 wherein HAA is Npg which may be N-alpha-methylated ;

and its pharmaceutically acceptable salts.

5 14. A pharmaceutical composition which contains an effective amount of a peptide analogue according to one of claims 1 to 13, or of a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition according to claim 14 for oral or parenteral administration.

10 16. Use of a peptide analogue according to one of claims 1 to 13 for the preparation of a medicament for the treatment of infertility, hypogonadic or hypergonadic states, wherein said peptide is used alone or in combination with a sex steroid or a gonadotrophin.

17. Use of a peptide analogue according to one of claims 1 to 13 for the preparation
15 of a contraceptive agent, wherein said peptide is used alone or in combination with a sex steroid or a gonadotrophin.

18. Use of a peptide analogue according to one of claims 1 to 13 for the preparation of a medicament for the treatment or prevention of prostate cancer or benign prostatic hypertrophy, wherein said peptide is used alone or in combination with an androgen
20 action inhibitor, a 5 α -reductase inhibitor or a C₁₇₋₂₀ lyase inhibitor.

19. Use of a peptide analogue according to one of claims 1 to 13 for the preparation of a medicament for the treatment or prevention of breast cancer, wherein said peptide is used alone or in combination with an antiestrogen, an aromatase inhibitor or a C₁₇₋₂₀ lyase inhibitor.

25 20. Use of a peptide analogue according to one of claims 1 to 13 for the preparation of a medicament for the treatment or prevention of sex hormone-related benign or malignant tumors, wherein said peptide is used alone or in combination with a hormonal or antitumoral agent.

21. Use of a peptide analogue according to one of claims 1 to 13 for the preparation
30 of a medicament for the treatment or prevention of sex hormone-independent but LH-RH sensitive benign or malignant tumors, wherein said peptide is used alone or in combination with an antitumoral agent.

22. Use of a peptide analogue according to one of claims 1 to 13 for the preparation of a medicament for the treatment or prevention of benign or malignant lymphoproliferative disorders, wherein said peptide is used alone or in combination with an immunomodulating agent or an immunosuppressive agent.
- 5 23. Use of a peptide analogue of formula (IIa) or (IIIa) according to one of claims 3 to 8 for the preparation of a medicament having LH-RH agonist activity.
24. Use of a peptide analogue of formula (IIb) or (IIIb) according to one of claims 9 to 13 for the preparation of a medicament having LH-RH antagonist activity.
25. Use of a non-aromatic hydrophobic amino acid having from 7 to 20 carbon
10 atoms in position 7 of a LH-RH analogue sequence for the preparation of a medicament having a high affinity for the LH-RH receptors.

52

AMENDED CLAIMS

[received by the International Bureau on 17 November 1998 (17.11.98);
original claims 1-25 replaced by new claims 1-27 (5 pages)]


1. A LH-RH peptide analogue, in which a non-aromatic hydrophobic amino acid having a side chain of from 5 to 18 carbon atoms is substituted for Leu⁷, provided that said amino acid is not Cha, Ser(Bu¹), Thr(Bu¹), Asp(OBu¹), Glu(OBu¹), Orn(Boc) or Lys(Boc); and its pharmaceutically acceptable salts.
2. A peptide analogue according to claim 1 in which Ada⁷ or Npg⁷ is substituted for Leu⁷; and its pharmaceutically acceptable salts.
3. A peptide analogue according to claim 1, of the formula (SEQ ID N° : 1):
 10 A1-A2-A3 -A4-A5-A6-HAA-A7-Pro-Z (I)
 in which :
 - A1 is pGlu ; D-pGlu ; Sar ; AcSar ; Pro ; AcPro ; ForPro ; OH-Pro ; Ac-OH-Pro ; dehydro-Pro ; Ac-dehydro-Pro ; Ser ; D-Ser ; Ac-D-Ser ; Thr ; D-Thr ; Ac-D-Thr ; or an aromatic D-amino acid which may be acylated;
 15 - A2 is a direct bond ; His ; or an aromatic D-amino acid;
 - A3 is an aromatic L- or D-amino acid;
 - A4 is Ala, Ser, D-Ser, MeSer, Ser(OBu¹), Ser(OBzl) or Thr;
 - A5 is an aromatic L-amino acid or a basic L- or D-amino acid;
 - A6 is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu¹) ; D-Asp(OBu¹) ; D-Glu(OBu¹) ; D-Thr(OBu¹) ; D-Cys(OBu¹) ;
 20 D-Ser(OR₁) where R₁ is a sugar moiety ; an aza-amino acid; D-His which may be substituted on the imidazole ring by a (C₁-C₆)alkyl or by a (C₂-C₇)acyl group ; an aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl side chain ; an aromatic D-amino acid ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic L- or D-amino acid;
 25 - HAA is a non-aromatic amino acid having a side chain of from 5 to 18 carbon atoms, provided that said amino acid is not Cha, Ser(Bu¹), Thr(Bu¹), Asp(OBu¹), Glu(OBu¹), Orn(Boc) or Lys(Boc) ;
 - A7 is a basic L- or D-amino acid;
 30 - Z is GlyNH₂ ; D-AlaNH₂ ; azaGlyNH₂ ; or a group -NHR₂ where R₂ is a (C₁-C₄)alkyl which may be substituted by an hydroxy or one or several fluorine atoms, a

(C₃-C₆)cycloalkyl or a heterocyclic radical selected from morpholinyl, pyrrolidinyl and piperidyl;

and its pharmaceutically acceptable salts.

4. A peptide analogue according to claim 3, in which HAA is Ada or Npg ; and
5 its pharmaceutically acceptable salts.


5. A peptide analogue according to claim 3, of the formula (SEQ ID N° : 2) :



in which :

- A1 is pGlu, Sar or AcSar;
 - 10 - A2 is His;
 - A3 and A4 are as defined for (I) in claim 3;
 - A5 is an aromatic L-amino acid;
 - A6 is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu¹) ; D-Asp(OBu¹) ; D-Glu(OBu¹) ; D-Thr(OBu¹) ; D-Cys(OBu¹) ;
 - 15 D-Ser(OR₁) where R₁ is a sugar moiety ; an aza-amino acid; D-His which may be substituted on the imidazole ring by a (C₁-C₆)alkyl or by a (C₂-C₇)acyl group ; an aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl side chain ; an aromatic D-amino acid ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic D-amino acid;
 - 20 - HAA is as defined for (I) in claim 3;
 - A7 is a basic L-amino acid;
 - Z is GlyNH₂, azaGlyNH₂ or a group -NHR₂ where R₂ is as defined for (I) in claim 3;
- and its pharmaceutically acceptable salts.

25 6. A peptide analogue according to 5, of the formula (SEQ ID N° : 4) :



in which :

- A3 and HAA are as defined for (I) in claim 5 ;
- A6 is Gly ; and aliphatic D-amino acid with a (C₁-C₈)alkyl side chain ; or an
- 30 aromatic D-amino acid ;
- Z is GlyNH₂ or a group -NHC₂H₅ ;

and its pharmaceutically acceptable salts.

7. A peptide analogue according to claim 6 wherein A3 is Trp ;
and its pharmaceutically acceptable salts.

8. A peptide analogue according to one of claims 5 to 7 wherein HAA is Ada or
5 Npg where Npg may be N-alpha substituted by a (C₁-C₄)alkyl group which may be
substituted by one or several fluorine atoms ;
and its pharmaceutically acceptable salts.

9. A peptide analogue according to claim 8 wherein HAA is Npg where Npg
10 may be N-alpha substituted by a (C₁-C₄)alkyl group which may be substituted by one
or several fluorine atoms ;
and its pharmaceutically acceptable salts.

10. A peptide analogue according to claim 9 wherein HAA is Npg which may be
N-alpha-methylated ;
and its pharmaceutically acceptable salts.

15 11. A peptide analogue according to claim 3, of the formula (SEQ ID N° : 3) :



in which :

- A1 as defined for (I) in claim 3;
 - A2 is a direct bond or an aromatic D-amino acid;
 - 20 - A3, A4 and A5 are as defined for (I) in claim 3;
 - A6 is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu^t) ; D-Asp(OBu^t) ; D-Glu(O-Bu^t) ; D-Thr(O-Bu^t) ; D-Cys(O-Bu^t) ; D-Ser(O-R₁) where R₁ is a sugar moiety ; an aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl side chain ; an aromatic D-amino acid ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic
25 L- or D-amino acid;
 - HAA and A7 are as defined for (I) in claim 3;
 - Z is GlyNH₂ or D-AlaNH₂;
- and its pharmaceutically acceptable salts.

30 12. A peptide analogue according to claim 11, of the formula (SEQ ID N° : 5) :

Ac-D-Nal-D-pClPhe-D-Pal-Ser-A5-A6-HAA-A7-Pro-D-AlaNH₂ (IIIb)

in which:

- A5 is as defined for (IIb) in claim 11;
- A6 is Gly or a basic L- or D- amino acid;
- 5 - HAA and A7 are as defined for (IIb) in claim 11;
and its pharmaceutically acceptable salts.
- 13. A peptide analogue according to claim 11 or 12 wherein HAA is Ada or Npg where Npg may be N-alpha substituted by a (C₁-C₄)alkyl group which may be substituted by one or several fluorine atoms ;
10 and its pharmaceutically acceptable salts.
- 14. A peptide analogue according to claim 13 wherein HAA is Npg where Npg may be N-alpha substituted by a (C₁-C₄)alkyl group which may be substituted by one or several fluorine atoms ;
and its pharmaceutically acceptable salts.
- 15 15. A peptide analogue according to claim 14 wherein HAA is Npg which may be N-alpha-methylated ;
and its pharmaceutically acceptable salts.
- 16. A pharmaceutical composition which contains an effective amount of a peptide according to one of claims 1 to 15, or of a pharmaceutically acceptable salt
20 thereof.
- 17. A pharmaceutical composition according to claim 16 for oral or parenteral administration.
- 18. Use of a peptide according to any one of claims 1 to 15 for the preparation of a medicament for the treatment of infertility, hypogonadic or hypergonadic states,
25 wherein said peptide is used alone or in combination with a sex steroid or a gonadotrophin.
- 19. Use of a peptide according to any one of claims 1 to 15 for the preparation of a contraceptive agent, wherein said peptide is used alone or in combination with a sex steroid or a gonadotrophin.

20. Use of a peptide according to any one of claims 1 to 15 for the preparation of a medicament for the treatment or prevention of prostate cancer or benign prostatic hypertrophy, wherein said peptide is used alone or in combination with an androgen action inhibitor, a 5 α -reductase inhibitor or a C₁₇₋₂₀ lyase inhibitor.
- 5 21. Use of a peptide according to any one of claims 1 to 15 for the preparation of a medicament for the treatment or prevention of breast cancer, wherein said peptide is used alone or in combination with an antiestrogen, an aromatase inhibitor or a C₁₇₋₂₀ lyase inhibitor.
22. Use of a peptide according to any one of claims 1 to 15 for the preparation of
10 a medicament for the treatment or prevention of sex hormone-related benign or malignant tumors, wherein said peptide is used alone or in combination with a hormonal or antitumoral agent.
23. Use of a peptide according to any one of claims 1 to 15 for the preparation of
15 LH-RH sensitive benign or malignant tumors, wherein said peptide is used alone or in combination with an antitumoral agent.
24. Use of a peptide according to any one of claims 1 to 15 for the preparation of a medicament for the treatment or prevention of benign or malignant lymphoproliferative disorders, wherein said peptide is used alone or in combination
20 with an immunomodulating agent or an immunosuppressive agent.
25. Use of a peptide of formula (IIa) or (IIIa) according to one of claims 5 to 10 for the preparation of a medicament having LH-RH agonist activity.
26. Use of a peptide of formula (IIb) or (IIIb) according to one of claims 11 to 15 for the preparation of a medicament having LH-RH antagonist activity.
- 25 27. Use of a non-aromatic hydrophobic amino having a side chain of from 5 to 18 carbon atoms in position 7 of a LH-RH analogue sequence for the preparation of a medicament having a high affinity for the LH-RH receptors, provided that said amino acid is not Cha, Ser(Bu^t), Thr(Bu^t), Asp(OBu^t), Glu (OBu^t), Orn(Boc) or Lys(Boc).

1/1




FIG.1

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 98/02802

| A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C07K7/23 A61K38/09 | | |
|---|--|--|
| According to International Patent Classification (IPC) or to both national classification and IPC | | |
| B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07K A61K | | |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched | | |
| Electronic data base consulted during the international search (name of data base and, where practical, search terms used) | | |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT | | |
| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| X | E. HAZUM ET AL.: "Synthesis, biological activity and resistance to enzymic degradation of LHRH analogues modified at position 7" FEBS LETTERS, vol. 123, no. 2, January 1981, pages 300-302, XP002076393 see the whole document see figure 1 | 1-5,9, 14,15, 23-25 |
| X | WO 91 05563 A (UNIV TULANE) 2 May 1991 see abstract see claim 1 | 1-5,9, 14-25 |
| -/- | | |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. | | |
| <input checked="" type="checkbox"/> Patent family members are listed in annex. | | |
| * Special categories of cited documents: | | |
| "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family | | |
| Date of the actual completion of the international search 3 September 1998 | | Date of mailing of the international search report 24/09/1998 |
| Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 | | Authorized officer Cervigni, S |

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 98/02802

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | DE 24 24 287 A (HOECHST AG) 4 December 1975 see page 5, last paragraph see page 1 | 1-5, 9, 14-25 |
| A | KARTEN M J ET AL: "GONADOTROPIN-RELEASING HORMONE ANALOG DESIGN. STRUCTURE-FUNCTION STUDIES TOWARD THE DEVELOPMENT OF AGONISTS AND ANTAGONISTS: RATIONALE AND PERSPECTIVE" ENDOCRINE REVIEWS, vol. 7, no. 1, 1986, pages 44-66, XP002038872 see page 48, column 1, last paragraph see page 56, column 2, last paragraph - page 57, column 1 | |
| A | US 5 470 947 A (FOLKERS KARL A ET AL) 28 November 1995 | |
| A | DE 23 21 174 A (TAKEDA CHEMICAL INDUSTRIES LTD) 8 November 1973 | |

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/02802

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|--|------------------|-------------------------|------------------|
| WO 9105563 A | 02-05-1991 | US 5003011 A | 26-03-1991 |
| | | CA 2044137 A | 14-04-1991 |
| | | EP 0448687 A | 02-10-1991 |
| | | GR 90100752 A | 20-03-1992 |
| | | PT 95596 A | 13-09-1991 |
| DE 2424287 A | 04-12-1975 | BE 829269 A | 20-11-1975 |
| | | CA 1051873 A | 03-04-1979 |
| | | CH 613441 A | 28-09-1979 |
| | | DK 218175 A | 19-11-1975 |
| | | FR 2270890 A | 12-12-1975 |
| | | GB 1512433 A | 01-06-1978 |
| | | JP 51001469 A | 08-01-1976 |
| | | LU 72501 A | 10-02-1977 |
| | | NL 7505590 A | 20-11-1975 |
| | | US 4003884 A | 18-01-1977 |
| US 5470947 A | 28-11-1995 | US 4935491 A | 19-06-1990 |
| | | US 5763404 A | 09-06-1998 |
| | | AT 124957 T | 15-07-1995 |
| | | AU 2529488 A | 31-03-1989 |
| | | DE 3854159 D | 17-08-1995 |
| | | DE 3854159 T | 15-02-1996 |
| | | DK 48690 A | 19-04-1990 |
| | | EP 0377665 A | 18-07-1990 |
| | | HU 213098 B | 28-02-1997 |
| | | HU 9500574 A | 30-10-1995 |
| | | JP 2621970 B | 18-06-1997 |
| | | JP 3501969 T | 09-05-1991 |
| | | MX 9203688 A | 01-09-1992 |
| | | NO 301015 B | 01-09-1997 |
| | | NO 942179 A | 23-04-1990 |
| | | OA 9786 A | 15-04-1994 |
| | | WO 8901944 A | 09-03-1989 |
| DE 2321174 A | 08-11-1973 | JP 949172 C | 20-04-1979 |
| | | JP 49001562 A | 08-01-1974 |
| | | JP 53024423 B | 20-07-1978 |
| | | JP 949179 C | 20-04-1979 |
| | | JP 49075577 A | 20-07-1974 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 98/02802

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| DE 2321174 A | | JP 53024424 B | 20-07-1978 |
| | | AT 333988 B | 27-12-1976 |
| | | AT 349660 B | 25-04-1979 |
| | | AT 753275 A | 15-09-1978 |
| | | AU 453931 B | 17-10-1974 |
| | | AU 5467673 A | 17-10-1974 |
| | | BE 798114 A | 31-07-1973 |
| | | CA 1005815 A | 22-02-1977 |
| | | CH 580065 A | 30-09-1976 |
| | | CS 188162 B | 28-02-1979 |
| | | DE 2366379 C | 17-01-1985 |
| | | DK 147851 B | 24-12-1984 |
| | | DK 441083 A, B, | 27-09-1983 |
| | | FI 56676 B | 30-11-1979 |
| | | FR 2183021 A | 14-12-1973 |
| | | GB 1403642 A | 28-08-1975 |
| | | NL 7305995 A, C | 31-10-1973 |
| | | SE 397520 B | 07-11-1977 |
| | | US 3853837 A | 10-12-1974 |
| | | ZA 7302564 A | 27-03-1974 |

THIS PAGE RI ANK #1870

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record.

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☒ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE RI ANK #15PT01